摘要
【目的】观察沙利度胺对克罗恩病的临床疗效。【方法】选取邵阳市中心医院2004年1月至2007年8月份住院的46例轻中度克罗恩病患者,随机分成两组。治疗组23例,服用沙利度胺100mg/d,对照组23例,服用柳氮磺胺吡啶(SASP)4g/d,疗程8周,比较沙利度胺与SASP的疗效。【结果】采用沙利度胺治疗的临床缓解率26.08%(6/23),有效率65.22%(15/23),总有效率91.3%;对照组临床缓解率为21.74%(5/23),有效率56.52%(13/23),总有效率为78.26%。沙利度胺的总体疗效高于SASP,具有显著性差异(P<0.05)。【结论】沙利度胺对轻中度克罗恩病有效,其疗效优于传统的SASP,可望成为一种治疗克罗恩病的新型药物。
[Objective] To observe the effect of thalidomide for the treatment of Crohn＇s disease. [Methods] Forty six patients with mild and moderate Crohn＇s disease were randomly divided into two groups. The treatment group （ n =23） was given orally 100 microgram of thalidomide everyday, while the matched control group （ n = 23） was given 4000 microgram of salicylazosulfapyridine （SASP） everyday for 8 weeks. [Results] The overall efficacy of thalidomide and SASP was 91.3% and 78.26% respectively. The overall effective rate of thalidomide was higher than that of SASP. There was significant difference in the overall efficacy of the two groups （ P 〈0.05）. [Conclusion] Thalidomide is effective in treating mild and moderate Crohn ＇s disease. The effectiveness of thalidomide is higher than that of SASP. Thus thalidomide is expected to be a new drug to treat Crohn＇s disease.
出处
《医学临床研究》
CAS
2008年第4期647-648,共2页
Journal of Clinical Research
